Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus
Authors:
- 21 December 2015
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 36 (3) , 195-202
Abstract
Henagliflozin, a selective inhibitor of the renal sodium glucose cotransporter-2, was developed for type 2 diabetes mellitus (T2DM). This study characterized single- and multiple-dose pharmacokinetics and pharmacodynamics of henagliflozin in Chinese patients with T2DM. Thirty T2DM patients were randomized in a 4:1 ratio to orally receive either henagliflozin 5, 10, 20 mg/day or placebo for 10 days, except on day 2 and day 3. Pharmacokinetic and pharmacodynamic profiles were measured on day 1 and day 10. Henagliflozin exhibited dose-proportional plasma concentrations with a half-life ranging from 9.1 to 14 h. Steady-state plasma henagliflozin concentration was reached by day 7 in all active treatment groups. Henagliflozin decreased the 24-h mean plasma glucose by −0.3, −1.0 and −1.0 mmol/L with doses of 5, 10 and 20 mg on day 1, respectively. The corresponding values on day 10 were −0.8, −0.9 and −1.2 mmol/L. Twenty-four-hour urinary glucose excretion increased by 11, 65 and 82 times with doses of 5, 10 and 20 mg on day 1, respectively, with a similar trend on day 10. No treatment-related serious adverse events or discontinuations due to adverse events occurred. The observed pharmacokinetic and pharmacodynamic profiles of henagliflozin support a once-daily dosing regimen in Chinese T2DM patients.Keywords
This publication has 11 references indexed in Scilit:
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2Clinical Pharmacokinetics, 2013
- Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–glucose co‐transporter type 2, in Japanese subjects without and with type 2 diabetes mellitusDiabetes, Obesity and Metabolism, 2011
- Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy SubjectsClinical Pharmacology & Therapeutics, 2009
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes MellitusClinical Pharmacology & Therapeutics, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Active sugar transport in health and diseaseJournal of Internal Medicine, 2007
- Sergliflozin, a Novel Selective Inhibitor of Low-Affinity Sodium Glucose Cotransporter (SGLT2), Validates the Critical Role of SGLT2 in Renal Glucose Reabsorption and Modulates Plasma Glucose LevelThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Type-2 diabetes: a cocktail of genetic discoveryHuman Molecular Genetics, 2006
- The emerging pandemic of obesity and diabetes: are we doing enough to prevent a disaster?International Journal Of Clinical Practice, 2006
- Antihyperglycemic Effect of T-1095 via Inhibition of Renal Na+-Glucose Cotransporters in Streptozotocin-Induced Diabetic Rats.Biological and Pharmaceutical Bulletin, 2000